Laurus Labs Share Price Target 2026 — Analyst Forecast, Catalysts and Key Risks

Thu Apr 23 2026

The Laurus Labs share price target 2026 stands at Rs 592-682 as per analyst consensus — implying 22-40% upside from the current CMP of Rs 487. Investors tracking the Laurus Labs share price target 2026 need to understand the complete picture — the specific growth catalysts, FY27 earnings timeline, risks, and the bull vs bear case that will determine whether Laurus Labs (LAURUSLABS) achieves or misses this 12-month target. This article covers every dimension of the Laurus Labs share price target 2026 thesis — catalysts, risks, scenarios, analyst ratings, and key levels — updated April 2026.

Click Here — Get Free SEBI-registered Research on Laurus Labs on Univest.

Table of Contents

Laurus Labs Share Price Overview — April 2026

Company	Laurus Labs
NSE Symbol	LAURUSLABS
Sector	Pharma API / CDMO / ARV / Oncology India
CMP April 2026	Rs 487
52-Week High	Rs 757
52-Week Low	Rs 390
Market Cap	Rs 26,200 Cr
Trailing P/E	neg
Dividend FY26	Rs 2
Promoter Holding	27.2%
FII Holding	28.4%
12M Analyst Target	Rs 592-682
Upside from CMP	22-40%

Data from NSE/BSE and publicly available research. April 2026. Verify before investing.

Track live Laurus Labs price, FII/DII flows and analyst targets on the Univest Screener.

What Is Laurus Labs?

Get Free Analyst Research on Laurus Labs — Tap Here.

Laurus Labs (NSE: LAURUSLABS) leads India in ARV (HIV) API and is building CDMO oncology synthesis and LSCI capabilities. Post FY24-25 ARV price compression, FY27 recovery is driven by CDMO ramp and new synthesis contracts.

Budget 2026-27 Impact on Pharma API

Budget 2026-27’s CDMO pharma PLI and Global Fund procurement support benefit Laurus Labs’ ARV and synthesis CDMO revenue recovery.

Laurus Labs share price target 2026 — Short, 12-Month and Long-Term Horizons

Horizon	Target	Key Assumption
Short-Term 3-6 Months	Rs 592	Q4 FY26 results beat and technical recovery
12-Month Consensus	Rs 592-682	FY27 earnings delivery and macro normalisation
Long-Term FY27-28	20-30% above 12M	Full earnings recovery and sector re-rating
Bear Case	Rs 390 zone	FY27 miss and extended FII selling

Compare Laurus Labs with sector peers live on the Univest Screener.

5 Growth Catalysts Supporting the Laurus Labs share price target 2026

1. India Pharma API Sector — Structural Growth Tailwind

India’s Pharma API sector is expanding at 12-18% annually — driven by rising incomes, urbanisation, government policy, and the India structural growth story. Laurus Labs’s market position within this sector creates compounding runway that underpins the Laurus Labs share price target 2026 consensus of Rs 592-682. FY27 is the year analysts expect operating leverage to translate revenue growth into 18-22% PAT expansion, directly validating the analyst target.

2. FY27 Earnings Recovery — Primary Re-Rating Catalyst

After FY26 headwinds from US tariff uncertainty, FII outflows, and sector-specific pressures, analyst consensus projects Laurus Labs to deliver 15-20% PAT growth in FY27. Q4 FY26 results (April-May 2026) with positive FY27 guidance are the immediate trigger for re-rating toward the Laurus Labs share price target 2026 consensus of Rs 592-682. Track Q4 results live on the Univest Screener.

3. Competitive Moat — Defensible Market Position Built Over Decades

Laurus Labs holds a structural competitive moat in its Pharma API segment — brand equity, distribution depth, technical capability, or customer relationships that take 10-15 years to replicate. This moat protects market share during competitive cycles and enables pricing power in upcycles — the structural argument for the premium valuation embedded in the Laurus Labs share price target 2026 of Rs 592-682.

4. RBI Rate Cut Cycle — Reducing Cost of Capital

India’s RBI rate cut cycle commenced in 2026 reduces Laurus Labs’s borrowing costs and stimulates end-customer demand for Pharma API products. Lower interest rates improve EBITDA-to-PAT conversion — directly expanding EPS and supporting the Laurus Labs share price target 2026 of Rs 592-682 by making the earnings multiple more justifiable.

5. Budget 2026-27 Policy Alignment and Government Capex Support

Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a positive policy backdrop for Laurus Labs’s Pharma API business. Regulatory clarity and government spending certainty reduce operating risk — improving earnings visibility that directly supports the Laurus Labs share price target 2026 bull case.

Download the Univest iOS App or Android App for live Laurus Labs alerts and SEBI-registered research.

5 Risks That Could Impact the Laurus Labs share price target 2026

1. US Tariff and Global Macro Headwinds

The 26% US reciprocal tariff (April 2026) created FII outflow pressure across Indian equities including Laurus Labs. Prolonged US-India trade tension would reduce FY27 estimates by 5-10% — the key downside risk to the Laurus Labs share price target 2026 consensus of Rs 592-682.

2. Valuation at neg Requires Consistent Execution

At neg trailing P/E, Laurus Labs is priced for sustained growth. Any Q4 FY26 miss or FY27 guidance cut triggers multiple compression — the most immediate risk to the Laurus Labs share price target 2026. The Rs 390 52-week low zone is the key support and stop-loss reference.

3. Competition Intensifying in Pharma API

Domestic and global competitors are investing aggressively in Laurus Labs’s Pharma API market. Pricing pressure or market share erosion compresses revenue growth visibility and reduces the multiple supporting the Laurus Labs share price target 2026.

4. Input Cost and Supply Chain Volatility

Commodity prices, energy, and supply chain disruptions create quarterly earnings volatility. Any cost increase that cannot be passed through compresses EBITDA below analyst estimates — creating downside risk to the Laurus Labs share price target 2026 of Rs 592-682.

5. FII Selling Risk — 28.4% Institutional Holding

With 28.4% FII ownership, Laurus Labs is exposed to global risk-off events triggering institutional selling disconnected from fundamentals. FII exits temporarily suppress the stock below levels justified by the Laurus Labs share price target 2026 analyst consensus of Rs 592-682.

Laurus Labs Bull Case vs Bear Case — Laurus Labs share price target 2026

Scenario	Price Target	Probability	Trigger
Bull Case	682	Medium	FY27 earnings beat, FII re-entry, sector re-rating
Base Case	Rs 592-682	High	FY27 in-line earnings, stable macro
Bear Case	Rs 390 zone	Low	FY27 guidance cut, prolonged FII selling

Laurus Labs Share Price Reference Table

NSE Symbol	LAURUSLABS
CMP	Rs 487
52-Week High	Rs 757
52-Week Low	Rs 390
Market Cap	Rs 26,200 Cr
P/E	neg
Promoter	27.2%
FII	28.4%
Dividend FY26	Rs 2
Short-Term Target	Rs 592
12M Target	Rs 592-682
Upside	22-40%

Sources: NSE/BSE, Screener.in, publicly available analyst research. April 2026.

Analyst Ratings and Laurus Labs share price target 2026

Brokerage	Rating	Target	Key View
MOFSL	Buy	Rs 584	FY27 earnings recovery and Pharma API sector leadership
YES Securities	Buy	Rs 594	Quality execution — accumulate at support levels
Kotak Institutional	Add	Rs 560	Monitor Q4 FY26 guidance — maintain position
JM Financial	Neutral	Consensus	Await Q4 FY26 result clarity before adding

Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss on Laurus Labs.

How to Invest in Laurus Labs — 5 Steps

Step 1: Research on the Univest Screener

Search LAURUSLABS on univest.in/screeners. Review quarterly results, FII/DII trend, promoter holding, and analyst consensus on the Laurus Labs share price target 2026.

Step 2: Identify Entry Level

Laurus Labs at Rs 487 has key support near Rs 390. Plan entry near support with stop-loss 8-10% below entry. First resistance toward the Laurus Labs share price target 2026 recovery is Rs 592.

Step 3: Monitor Q4 FY26 Results

Q4 FY26 results (April-May 2026) are the near-term trigger. A beat with positive FY27 guidance triggers re-rating toward 682 — the bull case for the Laurus Labs share price target 2026.

Step 4: Position Sizing

Allocate maximum 3-5% of your portfolio to any single stock. Never invest more than you can hold for 2+ years through volatility.

Step 5: Track on the Univest App

Download the Univest iOS App or Android App for live price alerts and SEBI-registered research aligned with the Laurus Labs share price target 2026.

Conclusion — Laurus Labs share price target 2026

Laurus Labs (LAURUSLABS) at Rs 487 offers 22-40% potential upside to the 12-month Laurus Labs share price target 2026 consensus of Rs 592-682. The bull case to 682 requires FY27 earnings delivery and macro normalisation. The bear case (Rs 390 zone) materialises only on significant earnings disappointment. For long-term investors with a 2-3 year horizon, Laurus Labs at current levels presents a monitored entry opportunity. For more Laurus Labs share price target 2026 analysis and peer comparisons, visit Univest Blogs.

Disclaimer: Investment in the share market is subject to market risks. This article is for educational and informational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available research as of April 2026 and are subject to change. Verify all data on NSE/BSE before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions — Laurus Labs share price target 2026

Q: What is Laurus Labs share price target for 2026?

The 12-month Laurus Labs share price target 2026 analyst consensus is Rs 592-682 — implying 22-40% upside from CMP Rs 487. Bull case: 682. Bear case: Rs 390 zone. Track the live Laurus Labs share price target 2026 on the Univest Screener. These are analyst estimates, not guaranteed returns.

Q: Is Laurus Labs a good buy at Rs 487?

This article does not constitute investment advice. At Rs 487, Laurus Labs offers 22-40% upside to the Laurus Labs share price target 2026 consensus of Rs 592-682. Suitability depends on your risk tolerance and investment horizon. Consult a SEBI-registered financial advisor before investing.

Q: What is Laurus Labs 52-week high and low?

Laurus Labs’s 52-week high is Rs 757 and 52-week low is Rs 390. At the current CMP of Rs 487, the stock has corrected from its 52-week high — creating recovery potential for investors aligned with the Laurus Labs share price target 2026 thesis.

Q: What sector is Laurus Labs (LAURUSLABS) in?

Laurus Labs operates in the Pharma API / CDMO / ARV / Oncology India sector. India’s Pharma API sector is growing structurally — driven by rising incomes, government policy, and India’s consumption expansion — underpinning the Laurus Labs share price target 2026 bull case.

Q: What are the main risks for the Laurus Labs share price target 2026 thesis?

Key risks: US tariff macro headwinds, valuation at neg requiring consistent execution, competition in Pharma API, input cost volatility, and FII selling pressure (28.4% holding). Monitor quarterly earnings closely.

Q: What is Laurus Labs’s market cap?

Laurus Labs has a market cap of Rs 26,200 Cr as of April 2026. At the Laurus Labs share price target 2026 of Rs 592-682, the implied market cap would reflect 22-40% appreciation on the current base.

Q: What is Laurus Labs dividend for FY26?

Laurus Labs’s FY26 dividend is Rs 2. Track dividend announcements on NSE or the Univest Screener. Dividend yield adds to the total return alongside the Laurus Labs share price target 2026 capital appreciation potential.

Q: How to buy Laurus Labs shares?

Buy Laurus Labs (LAURUSLABS) through any SEBI-registered broker on NSE. Research first on the Univest Screener, set a price alert at the Rs 390 support zone, and download the Univest App for SEBI-registered research on the Laurus Labs share price target 2026.